Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer

Cancer

Volumn 118, Issue 13, 2012, Pages 3244-3253

  Buzdar, Aman ^a   Vogel, Charles ^b   Schwartzberg, Lee ^c   Garin, August ^d   Perez, Alejandra ^e   Ingle, James ^f   Houghton, Michele ^g   Zergebel, Christopher ^g   Kimball, Bill ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b Lynn Cancer Institute   (United States)

^c Medical Oncology Hematology   (United States)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e MEMORIAL REGIONAL HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g Taiho Pharma USA Inc   (United States)

^h IQVIA   (United States)

Author keywords

Antiestrogen; Breast cancer; Hormone receptor positive; Metastatic disease; TAS 108

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTHRALGIA; ARTICLE; ASIAN; BACKACHE; BONE DENSITY; BREAST CANCER; CANCER GRADING; CAUCASIAN; CHILE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ETHNIC DIFFERENCE; FATIGUE; FEMALE; HEADACHE; HISPANIC; HOT FLUSH; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MEXICO; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEGRO; PACIFIC ISLANDER; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RUSSIAN FEDERATION; SAMPLE SIZE; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE;

EID: 84862539008     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26419     Document Type: Article

References (20)

1. Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005; 11: 315-322. (Pubitemid 40075810)
2. Buzdar AU,. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003; 8: 335-341. (Pubitemid 36934482)
3. Rugo HS,. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008; 19: 16-27.
4. Lim HS, Lee HJ, Lee KS, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25: 3837-3845. (Pubitemid 47477258)
5. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005; 23: 9312-9318.
6. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007; 25: 5187-5193. (Pubitemid 350232249)
7. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008; 99: 995-999. (Pubitemid 351997603)
8. Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
9. Coombes RC, Kilburn LS, Snowdon CF,. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369: 559-570 [erratum in Lancet. 2007;369:906].
10. Yamamoto Y, Wada O, Takada I, et al. Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun. 2003; 312: 656-662. (Pubitemid 37468221)
11. Toko T, Shibata J, Sato K, et al. Antiestrogenic/estrogenic activities of TAS108 (SR16234), a new selective steroidal estrogen receptor modulator [abstract]. Breast Cancer Res Treat. 1999; 57: 52.
12. Blakely LJ, Buzdar A, Chang HY, et al. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004; 10: 5425-5431. (Pubitemid 39100479)
13. Saeki T, Noguchi S, Aogi K, Inaji H, Habei T, Ikeda T,. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Ann Oncol. 2009; 20: 868-873.
14. Simon R,. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10. (Pubitemid 19099520)
15. Panageas KS,. An optimal 2-stage phase II design utilizing complete and partial response information separately. Control Clin Trials. 2002; 4: 367-379. (Pubitemid 34874889)
16. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000; 18: 2234-2244. (Pubitemid 30350215)
17. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26: 1664-1670.
18. Thurlimann B, Robertson JFR, Bonneterre J, et al. on Behalf of the Arimidex Study Group. Efficacy of tamoxifen following Arimidex (anastrozole) as first-line treatment for advanced breast cancer (ABC) in postmenopausal (PM) women [abstract]. Breast Cancer Res Treat. 2000; 64: 51. Abstract 162.
19. Yamaya H, Yoshida K, Kuritani J, et al. Safety, tolerability and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther. 2005; 30: 459-470. (Pubitemid 41603021)
20. Kumagai Y, Fujita T, Ozaki M, et al. Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study. Basic Pharmacol Toxicol. 2009; 104: 352-359.